Barclays PLC Acquires 44,022 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Barclays PLC lifted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 17.7% during the third quarter, HoldingsChannel reports. The firm owned 292,795 shares of the company’s stock after acquiring an additional 44,022 shares during the quarter. Barclays PLC’s holdings in Intellia Therapeutics were worth $6,017,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Blue Trust Inc. increased its stake in Intellia Therapeutics by 1,664.3% during the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after purchasing an additional 1,398 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after buying an additional 1,550 shares in the last quarter. Eastern Bank acquired a new position in shares of Intellia Therapeutics in the third quarter valued at approximately $41,000. First Horizon Advisors Inc. increased its position in shares of Intellia Therapeutics by 22.1% during the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after acquiring an additional 472 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new stake in shares of Intellia Therapeutics during the third quarter worth $54,000. Institutional investors own 88.77% of the company’s stock.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. The trade was a 4.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 3.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NTLA. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $90.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. Oppenheimer decreased their price objective on Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Monday, November 11th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. Wells Fargo & Company reduced their price target on Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating for the company in a research report on Monday, November 18th. Finally, Chardan Capital raised their price target on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.94.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $12.08 on Friday. Intellia Therapeutics, Inc. has a 52-week low of $11.79 and a 52-week high of $34.87. The company has a market capitalization of $1.23 billion, a P/E ratio of -2.22 and a beta of 1.76. The company has a 50-day simple moving average of $15.72 and a 200 day simple moving average of $20.36.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analyst estimates of $8.28 million. During the same period in the previous year, the business earned ($1.38) earnings per share. The business’s quarterly revenue was down 24.1% on a year-over-year basis. As a group, equities analysts forecast that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.